Mixed Results for Paxlovid in Standard Risk Patients With COVID-19
The study evaluated Paxlovid in both vaccinated and unvaccinated patients with COVID-19 at standard risk for progressing to severe disease.
The study evaluated Paxlovid in both vaccinated and unvaccinated patients with COVID-19 at standard risk for progressing to severe disease.
In a study, aviremic recipients of HCV-positive and HCV-negative deceased donor kidneys had similar 12-month transplant outcomes.
Molnupiravir is an orally administered form of a ribonucleoside analogue that inhibits the replication of SARS-CoV-2.
Oral antibiotics for urinary tract infections (UTIs) treatment chart including dosing and duration.
Types of COVID-19 vaccines in the US, including those approved by the FDA under Emergency Use Authorization, as well as other investigational products currently in Phase 3 clinical trials.
The approval was based on data from the phase 3 ACTT-2 and COV-BARRIER studies.
The approvals were based on data from pediatric trials evaluating treatment for complicated intra-abdominal infections and complicated urinary tract infections.
The FDA extended the review period due to ongoing discussions associated with pre-exposure prophylactic use of REGEN-COV.
Prevalence of discrimination was reported to be higher among all racial/ethnic minorities than among White participants; those who identify as Asian or American Indian/Alaska Native were most likely to have experienced hostile behavior.
As of April 5, 2022, CDC Nowcast data reported that the BA.2 subvariant accounted for more than 50% of cases in all US states and territories.